North West Cancer Research received has been honoured by Lancaster University after providing support of more than £2.5m over the last two decades to the institution’s research teams
A Liverpool-based charity dedicated to funding life-saving cancer research in the North West region has become the first organisation to be inducted into Lancaster University’s Chancellor’s College of Benefactors.
North West Cancer Research received the honour after providing support of more than £2.5m over the last two decades to the university’s research teams.
The charity is the biggest funder of cancer research at the university.
Its continued commitment has generated funding for basic, translational and clinical research, supporting clinicians, doctors, researchers and students.
This includes research projects, equipment, studentships and its highly acclaimed five-year research fellowships.
North West Cancer Research funding has boosted the understanding of cancers such as leukaemia, prostate and skin cancer.
Most recently, it has funded fundamental research which looks at the DNA of cancer cells and how they respond to damage.
Membership of the Chancellor’s College of Benefactors is the highest level of recognition bestowed upon the university’s donors and gives Lancaster the opportunity to acknowledge those organisations and individuals whose contributions have been truly transformational.
As a benefactor, North West Cancer Research will stand alongside other members of the Chancellor’s Guild, supporting the creation and development of innovative partnerships and global connections.
Lancaster University Chancellor, former Labour Minister Alan Milburn, said “Through the Chancellor’s College of Benefactors, the university is able to recognise the support of our most generous donors and celebrate the outcomes that have been achieved through their involvement.
“The support provided by North West Cancer Research over the years has funded a range of projects to help our researchers further understand the complexities of cancer, as well as enabling us to become a centre of excellence for cancer research.”